To implement a corporate restructuring, Becton Dickinson (BD) announced on Feb. 5, 2025, that it would proceed to “separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD.” The company plans to complete this action by the end of 2025. Clinical laboratories that buy BD products will be interested to learn that the […]
To access this post, you must purchase The Dark Report.